Recent innovations in DNA manufacturing are helping eliminate critical bottlenecks to bring new therapies to market faster than ever.
READNature reviews the latest advancements in DNA synthesis and the key challenges the new players like Elegen are quickly overcoming.
READBiocompare recently published on the challenges of scaling cell therapies. Part of this challenge starts UPSTREAM in determining the optimal DNA sequence for expansion–a time-consuming, resource-intensive process.
READMatt Hill, Founder and CEO of Elegen writes about the importance of innovation in DNA synthesis to address critical bottlenecks in biotherapy development.
READFeaturing Matt Hill - Founder & CEO of Elegen
LISTENDNA lengths of 15,000 base pairs and higher represent twice the length of the Company’s recently launched flagship product, ENFINIA DNA, and industry-leading complexity and turnaround time
READCompany focuses on ease of use, utility, and speed to increase ENFINIA DNA’s impact on workflow efficiency and productivity.
READGuest author John Cumbers, CEO of SynBioBeta meets with Elegen Founder and CEO, Matthew Hill
READMendelspod Podcast Featuring Elegen CEO and Founder, Matthew Hill
LISTENNote: GenomeWeb Premium Subscription Required
READ